Drug developers interested on the sexual dysfunction market are searching for the next Viagra.
Overview of erectile dysfunction, premature ejaculation and female sexual dysfunction disorders including epidemiology and key unmet needs.
Summary of the drug classes currently used for the different sexual dysfunction disorders and an update of the latest proposed treatment guidelines.
In the second published study, researchers at Tel Aviv University in Israel gave 46 men with erectile dysfunction either 5,000 mg of arginine or a placebo every day for six weeks.
In one, 21 of 24 men with erectile dysfunction who took ArginMax for four weeks reported improvement in their ability to maintain an erection during intercourse, compared to five of 24 men who were given a placebo.
Sexual dysfunction following onset of heart disease is common.
After stabilization and release from the hospital, many patients continue to show sexual dysfunction.
Treatment Platform Comprising Three Formulations Targets Opioid-Induced Bowel Dysfunction and Post-Operative Bowel Dysfunction
Methylnaltrexone is being developed in three dosage forms: subcutaneous and oral forms as treatment platforms for opioid-induced bowel dysfunction, and an intravenous form for post-operative bowel dysfunction.
suffer from erectile dysfunction (ED), also known as impotence.
To help couples better understand erectile dysfunction and various treatment options, the American Foundation for Urologic Disease (AFUD) is helping kick off Impotence Awareness Week, Nov.
This important patent underscores VIVUS' commitment to diversify its research and development efforts within urology beyond the treatment of male erectile dysfunction," stated Leland Wilson, President and CEO of VIVUS, Inc.
VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection.
One investor has described us as the only true restenosis company because we appear to be the only firm developing both drugs and devices to treat cardiovascular and vascular dysfunctions.
Comedicus Incorporated, which is privately held, develops restenosis systems for cardiovascular and vascular dysfunctions.